Breakout Ventures — 2022 Investments
4 investments dated 2022 · listed companies and verified rows first · show all
Cytovale develops microfluidic deformability cytometry technology for immune response diagnostics, with a focus on early detection and diagnosis in hospital settings.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Ajay Shah(Co-founder & CEO)inHenry Tse(Co-founder & Chief Technology Officer)inDino DiCarlo(Director, Promoter)
BoardJack Fuchs(Director, Promoter)in
Board seatLindy Fishburne· per SEC Form D
Co-investorsAlumni VenturesBasecamp FundBlackhorn VenturesBreakout LabsEMV CapitalIT-Farm Corporation+3 more
Checkerspot uses microalgae precision fermentation to produce specialized lipids and fats, including a bio-equivalent source of the sn-2 palmitate fat found in mother's milk, rare bioactive fatty acids, and tropical fat alternatives.
BiotechClimate TechFoodTechNew MaterialsAlameda, US
Scott Franklin(Executive Officer, Director)Charles Dimmler(Executive Officer, Director)John Krzywicki(CEO)Layla Ward(CFO)Casey Lippmeier(CTO)Leon Parker(SVP, Molecular Biology)
Board seatJulia (Thies) Moore· per SEC Form D
Co-investorsBaruch Future VenturesCavallo VenturesBuilders VCKdT VenturesRefactor Capital
Media, US
Peter Ledochowitsch(Executive Officer, Director)
Board seatLindy Fishburne· per SEC Form D · $3.5M raise · filed Jan 2022
Palo Alto, US
Bryan Mazlish(Executive Officer, Director)Jennifer Schneider(Executive Officer, Director)Ben Askew(Director)
Board seatLindy Fishburne· per SEC Form D · $16.3M raise · filed Apr 2022
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.